The Fed's Worst Nightmare ‘Just Got Worse' As Bitcoin Surges Toward $100,000 Price
Bitcoin has surged toward $100,000 per bitcoin, soaring this week to levels not seen since before the markets' tariff tantrum (and helped by a predicted $10 trillion Wall Street surprise).
Front-run Donald Trump, the White House and Wall Street by subscribing now to Forbes' CryptoAsset & Blockchain Advisor where you can "uncover blockchain blockbusters poised for 1,000% plus gains!"
The bitcoin price has added almost 30% since crashing to April lows as fears swirl around the future of the U.S. dollar.
Now, after a leak revealed growing establishment 'panic' over U.S. president Donald Trump's plans for bitcoin and crypto, analysts are warning a Federal Reserve 'nightmare' is coming true as data reveals the worst U.S. quarterly economic performance in three years.
Sign up now for the free CryptoCodex—A daily five-minute newsletter for traders, investors and the crypto-curious that will get you up to date and keep you ahead of the bitcoin and crypto market bull run
'The Fed's worst nightmare just got worse,' analysts with the The Kobeissi Letter posted to X. 'The market knows that stagflation has arrived. The Fed is facing the lose-lose situation they thought would never arrive.'
The analysts also pointed to the Fed's preferred personal consumption expenditures (PCE) price index data that was unchanged in March after advancing 0.4% in February.
"The PCE Price Index is now at its highest reading since July 2024, before the 'Fed pivot' began," Kobeissi analysts wrote.
In September, Fed chair Jerome Powell surprised markets with an interest rate cut, kicking off a monetary policy loosening cycle that's been on pause for months.
Kobeissi researchers have previously warned of the looming threat of 'stagflation,' referring to a combination of economic stagnation and climbing inflation.
'We have rising inflation with a weakening economy,' they wrote following this week's data drop. 'The Fed is officially in a lose-lose situation.'
Sign up now for CryptoCodex—A free, daily newsletter for the crypto-curious
The Fed will meet next week to decide whether to change interest rates, with the market currently predicting it will leave rates on hold.
However, traders are betting the Fed will begin cutting in June, something that's expected to boost the bitcoin price and risk assets.
"For bitcoin, such a scenario is a positive factor, since the easing of monetary policy traditionally leads to an influx of liquidity into risky assets," Tracy Jin, chief operating officer of bitcoin and crypto exchange MEXC, said in emailed comments.
Bitcoin's performance in recent months at first disappointed traders as the bitcoin price fell along with stocks in the face of Trump's escalating trade war.
However, the bitcoin price has surged back through April, making it one of the years better performing assets so far.
'Since president Trump's Liberation Day announcement, bitcoin has charted its own course, surging past $90,000 and demonstrating remarkable resilience against the headwinds affecting traditional markets," David Hernandez, crypto investment specialist at 21Shares, said via email.
'This outperformance relative to the Nasdaq represents a significant departure from historical patterns. As the impacts of president Trump's tariff policies begin to materialize more fully across the economy, we anticipate bitcoin could further disassociate from equities. The asset shows strong potential to outperform other risk assets as investors seek hedges against policy-driven market volatility.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
How Much the Average Middle-Class American Has Gained in the Stock Market Since Trump Announced His Tariffs
According to Gallup, 71% of middle-income Americans are invested in the stock market, and they've watched their fortunes rise and fall repeatedly during the volatile period since President Donald Trump announced his trade tariffs on April 2. But as the official start of summer approaches, those who resisted the urge to panic-sell during the frightening declines have largely seen their discipline pay off. Check Out: Read Next: It's impossible to gauge what the average middle-class investor might have gained or lost because the concept is a construct, regardless of the investor's socioeconomic class. Even if it were possible to put a dollar amount on the mean middle-class earner's stock investments, that would ignore critical variables like that investor's: Type, size and number of stock or fund holdings Portfolio makeup Portfolio diversity Degree of leverage from options trading or margin borrowing Trade frequency Fees and expenses Discover More: For context on just how differently two otherwise similar middle-class investors can perform, consider that Warner Bros Discovery Inc. (WBD) cratered on April 2 and retained a 24% overall loss through June 10. Conversely, Palantir Technologies Inc. (PLTR) has been one of the top performers in the post-tariff era, adding most of its 74% year-to-date gains since April 2. Two middle-class stock pickers with identical incomes and backgrounds who rolled the anti-diversification dice by purchasing identical amounts in either stock on April 1 would have had radically different outcomes between then and mid-June. A more reliable metric might be the major indices that so many middle-class households invest in through their 401(k)s, IRAs, index funds and ETFs. Between April 2 and June 10: The S&P 500, the benchmark index for the U.S. stock market, gained 6.16%. The Dow Jones Industrial Average, which tracks the blue chips, gained 1.31%. The tech-heavy and more volatile Nasdaq gained 11.57%. The FTSE All Cap Index, which includes much of the global stock market with 10,000 small-, mid- and large-cap companies in both developed and emerging markets, gained 7.22%. The average among all four is 6.57%, which is roughly what typical middle-class earners might have gained since April 2 if they followed the conventional advice of diversifying their portfolios with a blend of blue chips, growth stocks and foreign equities, and holding their positions regardless of market behavior. More From GOBankingRates 3 Luxury SUVs That Will Have Massive Price Drops in Summer 2025 Clever Ways To Save Money That Actually Work in 2025 7 Tax Loopholes the Rich Use To Pay Less and Build More Wealth This article originally appeared on How Much the Average Middle-Class American Has Gained in the Stock Market Since Trump Announced His Tariffs
Yahoo
27 minutes ago
- Yahoo
NHS faces paying more for US drugs to avoid future Trump tariffs
Britain faces paying more for US drugs as part of a deal to avoid future tariffs from Donald Trump. The NHS will review drug pricing to take into account the 'concerns of the president', according to documents released after a trade agreement was signed earlier this year. White House sources said it expected the NHS to pay higher prices for American drugs in an attempt to boost the interests of corporate America. A Westminster source said: 'There's an understanding that we would look at the drug pricing issue in the concerns of the president.' The disclosure is likely to increase concerns about American interference in the British health service, which has long been regarded as a flashpoint in trade talks. It comes after Rachel Reeves announced a record £29 billion investment in the NHS in last week's spending review. The Chancellor's plans will drive spending on the health service up towards 50 per cent of all taxpayer expenditure by the mid-2030s, according to economists at the Resolution Foundation. The Telegraph has also learnt that under the terms of the trade deal with America, the UK has agreed to take fewer Chinese drugs, in a clause similar to the 'veto' given to Mr Trump over Chinese investment in Britain. The White House has asked the UK for assurances that steel and pharmaceutical products exported to the US do not originate in China, amid fears the deal could be used to 'circumvent' Mr Trump's punishing tariffs on Beijing. Mr Trump is enraged by how much more America pays for drugs compared with other countries and considers it to be the same issue as he has raised on defence spending. Just as the US president has heaped pressure on European nations to increase the GDP share they allocate to defence, he thinks they should spend more on drug development. An industry source said: 'The way we've been thinking about it and many in the administration have been thinking about it, it's more like the model in Nato, where countries contribute some share of their GDP.' Britain and the US 'intend to promptly negotiate significantly preferential treatment outcomes on pharmaceuticals and pharmaceutical ingredients', the trade deal reads. Pharmaceutical companies are also pushing for reductions in the revenue sales rebates they pay to the NHS under the voluntary scheme for branded medicines pricing, access and growth (VPAG) – a mechanism that the UK uses to make sure the NHS does not overpay. Last week, Albert Bourla, Pfizer's chief executive, said non-US countries were 'free-riding' and called for a US government-led push to make other nations increase their proportionate spend on innovative medicines. He said White House officials were discussing drug prices in trade negotiations with other countries. 'We represent in UK 0.3pc of their GDP per capita. That's how much they spend on medicine. So yes, they can increase prices,' Mr Bourla said. Industry sources said there was no indication yet on what the White House would consider to be a fair level of spending. Whatever the benchmark, Britain will face one of the biggest step-ups. UK expenditure on new innovative medicines is just 0.28pc of its GDP, roughly a third of America's proportionate spending of 0.78pc of its GDP. Even among other G7 nations, the UK is an anomaly. Germany spends 0.4pc of its GDP while Italy spends 0.5pc. Most large pharmaceutical companies generate between half and three quarters of their profits in the US, despite the fact that America typically makes up less than a fifth of their sales. This is because drug prices outside of the US can cost as little as 30pc of what Americans pay. Yet, pharmaceutical companies rely on higher US prices to fund drug research and development, which the rest of the world benefits from. A month ago, Mr Trump signed an executive order titled 'Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients', which hit out at 'global freeloading' on drug pricing. It stated that 'Americans should not be forced to subsidise low-cost prescription drugs and biologics in other developed countries, and face overcharges for the same products in the United States' and ordered his commerce secretary to 'consider all necessary action regarding the export of pharmaceutical drugs or precursor material that may be fuelling the global price discrimination'. Trung Huynh, the head of pharma analysis at UBS, said: 'The crux of this issue is Trump thinks that the US is subsidising the rest of the world with drug prices. 'The president has said he wants to equalise pricing between the US and ex-US. And the way he wants to do it is not necessarily to bring down US prices all the way to where ex-US prices are, but he wants to use trade and tariffs as a pressure point to get countries to increase their prices. 'If he can offset some of the price by increasing prices higher ex-US, then the prices in America don't have to go down so much.' Mr Huynh added: 'It's going to be very hard for him to do. Because [in the UK deal] it hinges on the NHS, which we know has got zero money.' Under VPAG, pharmaceutical companies hand back at least 23pc of their revenue from sales of branded medicines back to the NHS, worth £3bn in the past financial year. The industry is pushing for this clawback to be cut to 10pc, which would mean the NHS would have to spend around 1.54bn more on the same medicines on an annual basis. The Government has already committed to reviewing the scheme, a decision which is understood to pre-date US trade negotiations. A government spokesman said: 'This Government is clear that we will only ever sign trade agreements that align with the UK's national interests and to suggest otherwise would be misleading. 'The UK has well-established and effective mechanisms for managing the costs of medicines and has clear processes in place to mitigate risks to supply.'
Yahoo
29 minutes ago
- Yahoo
The Fundamental Problem With MicroStrategy's Bitcoin-Buying Plan
MicroStrategy continues to add to its stockpile of Bitcoins, even as the price of the digital currency increases. At a higher price, adding to its position will become much more costly. The stock has been outpacing Bitcoin's rising valuation in the past year, but that trend may not hold up. 10 stocks we like better than Strategy › One of the hottest tech stocks in recent years has been MicroStrategy (NASDAQ: MSTR), which has rebranded itself as just Strategy. And a huge reason for its rally has been due to its bullish position on Bitcoin (CRYPTO: BTC) and its continual stockpiling of the digital currency. With the cryptocurrency soaring in value in recent years and breaching the $100,000 mark, Strategy has benefited from that excitement. But there's a fundamental problem with this approach. While it seems like a great way to benefit from the cryptocurrency's rising value, simply loading up on Bitcoins may not necessarily result in a higher share price for Strategy. In fact, it could end up hurting the stock down the road. Strategy is the largest corporate holder of Bitcoin, with its tally sitting at 582,000 Bitcoins as of June 9. Last year, it announced plans to raise as much as $42 billion, over a three-year period, in an effort to add to its crypto position, through a combination of both debt and equity. It shows a strong commitment to the digital currency, which has made the stock a popular option for crypto investors to load up on themselves. In five years, Strategy's stock has risen by over 3,000% while Bitcoin is up around 970%. And Executive Chairman Michael Saylor believes that through Bitcoin's rising valuation (he believes it'll surpass a price of $1 million in the future), Strategy may one day reach a valuation of $10 trillion. Today, its market cap is around $110 billion. But it may not be easy for Strategy to continue with its Bitcoin-buying spree if the digital currency soars in value. Strategy routinely purchases Bitcoins, but its average cost is now around $70,000. The company hasn't simply been buying Bitcoins at lower prices, it has also been loading up on them when the price has been above $100,000. The long-term problem is that the higher that Bitcoin goes in value, the more expensive it becomes for the company to add to its position. For investors, the problem centers around the need for ongoing capital raises. Right now, that may not be a big concern given how well Strategy's stock has been doing -- it's up around 150% in just the past 12 months. But stock offerings dilute existing shareholders and given Strategy's long-term plans to continually add Bitcoins, it has the potential to create an endless cycle of stock offerings followed by Bitcoin purchases. If the stock starts to slow down and can't keep up with a rising valuation for Bitcoin, it can result in greater share offerings necessary to fund future Bitcoin purchases. And the larger those offerings are, the more significant the downward pressure will be on the stock. The company sells business intelligence and analytics software but its core operations don't generate cash; Strategy has burned through more than $84 million just from its day-to-day operations over the past 12 months. Once you factor in its investing activities, which include Bitcoin purchases, the company's cash outflow ramps up to well over $28 billion. Rather than investing in a company because it hold Bitcoins, investors may want to consider directly investing in Bitcoin. Through spot exchange-traded funds, it's easier than ever to get a position in the cryptocurrency without worrying about digital wallets and having to remember complex passwords. Strategy's stock comes with added risk because more companies these days are also buying Bitcoin, and especially as its valuation creeps higher, investors may start to pivot from Strategy and into more modestly priced stocks that may possess greater upside. While investing in the tech stock has yielded great returns for investors thus far, that doesn't mean that pattern will continue, especially with its valuation now topping more than $100 billion. Without stronger fundamentals, Strategy is purely a speculative play involving crypto, which makes this an ultra-risky stock to be hanging on to, one that's likely not going to be suitable for the vast majority of investors. Before you buy stock in Strategy, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Strategy wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,702!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $870,207!* Now, it's worth noting Stock Advisor's total average return is 988% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 David Jagielski has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Bitcoin. The Motley Fool has a disclosure policy. The Fundamental Problem With MicroStrategy's Bitcoin-Buying Plan was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
